



The Future of
Molecular
Imaging

Gamma MRI

The Need

1

Over 165 million people in Europe are affected by at least one brain disease such as Alzheimer's, Parkinson's, dementia, stroke etc.

Most neurological diseases are aging sensitive and with the ongoing demographic changes, their incidence is expected to increase. This will be one of the major societal challenges in Europe and worldwide.

2

Stroke alone is the second most common cause of death and the third leading cause of disability worldwide.

Nearly 85% of strokes are of the ischaemic subtype that can be treated by restoring blood flow to the ischaemic brain through thrombolysis or thrombectomy. B

But only within a relatively narrow time window of 4–7 hours after ischemic onset.

3

The evolution of ischaemic damage varies much among patients and a careful selection of the patient's treatment path, based on imaging properties of the ischaemic brain, is essential to achieve significant improvement.

In the challenging move away from 'one size fits all' to personalized medicine, a multidisciplinary approach is required.



How to Improve

Molecular imaging at the cellular and molecular levels, of the processes involved in these diseases is an essential diagnostic tool to detect and correctly diagnose illnesses in an early stage of development.

What is Missing


Despite undergoing advances, current efforts in medical imaging (especially for the brain) rely on bulky, expensive and complex high-field MRI3, hybrid PET-MRI or PET-CT scanners



The GAMMA-MRI Proposition

The γ MRI project will develop a working prototype for in vivo molecular imaging, based on a revolutionary technology, allowing the simultaneous exploitation of the sensitivity of gamma (γ) detection and the spatial resolution and flexibility of MRI.

In essence, γ MRI will provide a groundbreaking technology for multi-tracer molecular imaging.



γ MRI is not just a hybrid approach combining separate modalities but a single new modality, simultaneously achieving the high spatial resolution of MRI and the high sensitivity of PET with faster scan time


Not requiring ultra-high MRI magnetic fields and expensive EM shielded rooms, nor detection of coincidence γ rays as in PET, γ MRI will be less complex and thus less expensive than present state-of-the-art devices, especially hybrid ones

This disruptive approach of a more accurate and widely available molecular imaging technology will pave new ways for patient care and medical imaging market


GAMMA-MRI will give access to biomarkers currently out of reach with state-of-the-art techniques. And the combined evaluation of related processes becomes possible (e.g. perfusion and metabolism).

Objectives

Develop a clinical molecular imaging device based on the physical principle of anisotropic gamma emission from hyperpolarised metastable Xenon



Allow the simultaneous exploitation of the sensitivity of gamma (γ) detection and the spatial resolution and flexibility of MRI



Produce a working prototype for in vivo molecular imaging





Gamma MRI

Scientific Highlights

1

γ MRI brings the spatial resolution of MRI (<1 mm) with the sensitivity of PET

2

γ MRI surpasses by 1000 times the enhanced sensitivity of hyperpolarised MRI bringing it to molecular imaging standards independently on the magnetic field. Weaker, with less requirements on homogeneity, and therefore cheaper magnetic fields can be used

3

Simultaneous high sensitivity and high resolution are possible in γ MRI. Positioning is given by MRI-sequences, asymmetry of γ -ray yields tracer amount

4

Several hyperpolarised radiotracers can be used simultaneously and easily be detected separately just based on the energy of the γ ray

5

γ MRI will develop new strategies to store hyperpolarised tracers for transport, from a central site of production to the imaging system

Expected Results

1

Production of hyperpolarised gamma-emitting xenon isomers – preserving hyperpolarisation until delivery to the targeted organ

2

Development of advanced image acquisition and reconstruction techniques using physics and artificial intelligence-based approaches

3

Design and assembling of a first prototype with a low-field versatile magnet

4

Achieve the first preclinical proof-of-concept brain imaging experiment



Current Status

The GAMMA-MRI project was started on the 1st of April 2021, and will finish on the 30th of September 2024.

In the last year significant progress has been achieved. The individual elements composing the system have been completed and the final prototype has been integrated.

The prototype is now undergoing a thoroughly testing phase.



The GAMMA-MRI Consortium



HAUTE ECOLE SPECIALISEE DE SUISSE
OCCIDENTALE
(Project Coordinator) <https://www.hesge.ch/>



EUROPEAN ORGANIZATION FOR
NUCLEAR RESEARCH (CERN)
<https://www.cern.eu/>



UNIVERSIDAD COMPLUTENSE DE MADRID
<https://www.ucm.es/>



Maastricht University
www.maastrichtuniversity.nl



KATHOLIEKE UNIVERSITEIT LEUVEN
<https://www.kuleuven.be/>



RS2D
<https://rs2d.com/>



INSPIRALIA
(Dissemination manager)
<https://www.inspiralia.com/>

Contact us



Mr. Ruben Rodriguez
Dissemination Manager
info@inspiralia.com
www.gamma-mri.eu



This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 964644



<https://www.linkedin.com/company/gamma-mri>



<https://twitter.com/gammamri>